Compare BKE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKE | TNGX |
|---|---|---|
| Founded | 1948 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 1996 | 2020 |
| Metric | BKE | TNGX |
|---|---|---|
| Price | $44.41 | $20.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $53.00 | $21.78 |
| AVG Volume (30 Days) | 437.2K | ★ 2.5M |
| Earning Date | 05-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | 6.43 | ★ 26.89 |
| EPS | ★ 4.14 | N/A |
| Revenue | ★ $1,297,835,000.00 | $62,384,000.00 |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $4.99 | N/A |
| P/E Ratio | $10.52 | ★ N/A |
| Revenue Growth | 6.58 | ★ 48.29 |
| 52 Week Low | $42.39 | $3.77 |
| 52 Week High | $61.69 | $28.41 |
| Indicator | BKE | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 42.30 |
| Support Level | N/A | $6.77 |
| Resistance Level | $56.45 | $22.01 |
| Average True Range (ATR) | 1.79 | 1.47 |
| MACD | -0.44 | -0.06 |
| Stochastic Oscillator | 19.26 | 6.95 |
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.